1 序文
2 範囲および方法論
2.1 本調査の目的
2.2 利害関係者
2.3 データソース
2.3.1 一次ソース
2.3.2 二次ソース
2.4 市場推定
2.4.1 ボトムアップアプローチ
2.4.2 トップダウンアプローチ
2.5 予測方法論
3 エグゼクティブサマリー
4 はじめに
4.1 概要
4.2 主要産業動向
5 世界の好中球減少症治療市場
5.1 市場概要
5.2 市場実績
5.3 COVID-19 の影響
5.4 市場予測
6 治療別市場内訳
6.1 コロニー刺激因子
6.1.1 市場動向
6.1.2 市場予測
6.2 抗生物質
6.2.1 市場動向
6.2.2 市場予測
6.3 抗真菌薬
6.3.1 市場動向
6.3.2 市場予測
6.4 抗ウイルス薬
6.4.1 市場動向
6.4.2 市場予測
7 流通チャネル別市場
7.1 病院薬局
7.1.1 市場動向
7.1.2 市場予測
7.2 小売薬局
7.2.1 市場動向
7.2.2 市場予測
7.3 オンライン薬局
7.3.1 市場動向
7.3.2 市場予測
8 地域別市場内訳
8.1 北米
8.1.1 米国
8.1.1.1 市場動向
8.1.1.2 市場予測
8.1.2 カナダ
8.1.2.1 市場動向
8.1.2.2 市場予測
8.2 アジア太平洋地域
8.2.1 中国
8.2.1.1 市場動向
8.2.1.2 市場予測
8.2.2 日本
8.2.2.1 市場動向
8.2.2.2 市場予測
8.2.3 インド
8.2.3.1 市場動向
8.2.3.2 市場予測
8.2.4 韓国
8.2.4.1 市場動向
8.2.4.2 市場予測
8.2.5 オーストラリア
8.2.5.1 市場動向
8.2.5.2 市場予測
8.2.6 インドネシア
8.2.6.1 市場動向
8.2.6.2 市場予測
8.2.7 その他
8.2.7.1 市場動向
8.2.7.2 市場予測
8.3 ヨーロッパ
8.3.1 ドイツ
8.3.1.1 市場動向
8.3.1.2 市場予測
8.3.2 フランス
8.3.2.1 市場動向
8.3.2.2 市場予測
8.3.3 英国
8.3.3.1 市場動向
8.3.3.2 市場予測
8.3.4 イタリア
8.3.4.1 市場動向
8.3.4.2 市場予測
8.3.5 スペイン
8.3.5.1 市場動向
8.3.5.2 市場予測
8.3.6 ロシア
8.3.6.1 市場動向
8.3.6.2 市場予測
8.3.7 その他
8.3.7.1 市場動向
8.3.7.2 市場予測
8.4 ラテンアメリカ
8.4.1 ブラジル
8.4.1.1 市場動向
8.4.1.2 市場予測
8.4.2 メキシコ
8.4.2.1 市場動向
8.4.2.2 市場予測
8.4.3 その他
8.4.3.1 市場動向
8.4.3.2 市場予測
8.5 中東およびアフリカ
8.5.1 市場動向
8.5.2 国別の市場内訳
8.5.3 市場予測
9 推進要因、阻害要因、機会
9.1 概要
9.2 推進要因
9.3 阻害要因
9.4 機会
10 バリューチェーン分析
11 ポーターのファイブフォース分析
11.1 概要
11.2 買い手の交渉力
11.3 売り手の交渉力
11.4 競争の度合い
11.5 新規参入の脅威
11.6 代替品の脅威
12 価格分析
13 競合状況
13.1 市場構造
13.2 主要企業
13.3 主要企業のプロフィール
Amgen Inc
BeyondSpring Inc
Kyowa Hakko Kirin Co. Ltd. (Kirin Holdings Company Limited)
Pfizer Inc
Sandoz Inc. (Novartis AG)
Spectrum Pharmaceuticals Inc
Teva Pharmaceutical Industries Ltd
Viatris Inc
Neutropenia is a disease characterized by an abnormally low count of white blood cells (WBCs) that help the body fight infections. It is caused by various situations or diseases, including infections, chemotherapy, congenital bone marrow abnormalities, autoimmune disorders, and some medications (drug-induced neutropenia). Neutrophils are made in the bone marrow, which is the spongy tissue found in larger bones, such as the vertebrae, ribs, and pelvis. Neutropenia treatment includes antibiotics, antifungals, and antiviral medications that help fight against infection by destroying harmful fungi, yeast, and bacteria that attack the body. These medications assist in reducing the likelihood of infections and stimulate the bone marrow to produce more white blood cells.
Neutropenia Treatment Market Trends:
The rising awareness of neutropenia and chemotherapy-related side effects is one of the key factors driving the market growth. In line with this, the increasing demand for oral drugs that are available in capsule and tablet form and consist of convenient routes of administration is favoring the market growth. Moreover, key players are actively engaged in disseminating relevant information and knowledge regarding preventive measures, early diagnosis, and effective treatment of neutropenia, which, in turn, is propelling the market growth. Furthermore, the increasing awareness among the masses regarding the available treatment alternatives is acting as another growth-inducing factor. In addition to this, manufacturers are focusing on the introduction of cost-effective medicines for neutropenia treatment, which is facilitating the market growth. Additionally, the utilization of novel drug delivery methods that helps in improving patient convenience, which leads to improved patient adherence, is positively influencing the market growth. Besides this, the increase in febrile neutropenia medications and the implementation of new legislation to promote and manufacture biosimilars are creating a positive outlook for the market. The market is also driven by the easy availability of medications through online retail portals, such as registered websites, which provides convenience of ordering and procurement of medications at affordable price-points. Other factors, including extensive research and development (R&D) activities, the introduction of innovative and effective drugs, rising incidences of cancer, easy access to healthcare facilities owing to improved infrastructure, increasing expenditure capacities of consumers and the implementation of various government initiatives for promoting public health, are anticipated to drive the market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global neutropenia treatment market, along with forecasts at the global, regional, and country level from 2025-2033. Our report has categorized the market based on treatment and distribution channel.
Treatment Insights:
Colony-Stimulating Factors
Antibiotics
Antifungals
Antivirals
The report has provided a detailed breakup and analysis of the neutropenia treatment market based on the treatment. This includes colony-stimulating factors, antibiotics, antifungals and antivirals. According to the report, colony-stimulating factors represented the largest segment.
Distribution channel Insights:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
The report has provided a detailed breakup and analysis of the neutropenia treatment market based on the distribution channel. This includes hospital, retail, and online pharmacies. According to the report, hospital pharmacies represented the largest segment.
Regional Insights:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for neutropenia treatment. Some of the factors driving the North America neutropenia treatment market included increasing demand for internet-enabled services by enterprises, extensive research and development (R&D) activities, and various technological advancements.
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global neutropenia treatment market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Amgen Inc., BeyondSpring Inc., Kyowa Hakko Kirin Co. Ltd. (Kirin Holdings Company Limited), Pfizer Inc., Sandoz Inc. (Novartis AG), Spectrum Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Questions Answered in This Report
1. How big is the global neutropenia treatment market?
2. What is the expected growth rate of the global neutropenia treatment market during 2025-2033?
3. What are the key factors driving the global neutropenia treatment market?
4. What has been the impact of COVID-19 on the global neutropenia treatment market?
5. What is the breakup of the global neutropenia treatment market based on the treatment?
6. What is the breakup of the global neutropenia treatment market based on the distribution channel?
7. What are the key regions in the global neutropenia treatment market?
8. Who are the key players/companies in the global neutropenia treatment market?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Neutropenia Treatment Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Treatment
6.1 Colony-Stimulating Factors
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Antibiotics
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Antifungals
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Antivirals
6.4.1 Market Trends
6.4.2 Market Forecast
7 Market Breakup by Distribution Channel
7.1 Hospital Pharmacies
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Retail Pharmacies
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Online Pharmacies
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by Region
8.1 North America
8.1.1 United States
8.1.1.1 Market Trends
8.1.1.2 Market Forecast
8.1.2 Canada
8.1.2.1 Market Trends
8.1.2.2 Market Forecast
8.2 Asia-Pacific
8.2.1 China
8.2.1.1 Market Trends
8.2.1.2 Market Forecast
8.2.2 Japan
8.2.2.1 Market Trends
8.2.2.2 Market Forecast
8.2.3 India
8.2.3.1 Market Trends
8.2.3.2 Market Forecast
8.2.4 South Korea
8.2.4.1 Market Trends
8.2.4.2 Market Forecast
8.2.5 Australia
8.2.5.1 Market Trends
8.2.5.2 Market Forecast
8.2.6 Indonesia
8.2.6.1 Market Trends
8.2.6.2 Market Forecast
8.2.7 Others
8.2.7.1 Market Trends
8.2.7.2 Market Forecast
8.3 Europe
8.3.1 Germany
8.3.1.1 Market Trends
8.3.1.2 Market Forecast
8.3.2 France
8.3.2.1 Market Trends
8.3.2.2 Market Forecast
8.3.3 United Kingdom
8.3.3.1 Market Trends
8.3.3.2 Market Forecast
8.3.4 Italy
8.3.4.1 Market Trends
8.3.4.2 Market Forecast
8.3.5 Spain
8.3.5.1 Market Trends
8.3.5.2 Market Forecast
8.3.6 Russia
8.3.6.1 Market Trends
8.3.6.2 Market Forecast
8.3.7 Others
8.3.7.1 Market Trends
8.3.7.2 Market Forecast
8.4 Latin America
8.4.1 Brazil
8.4.1.1 Market Trends
8.4.1.2 Market Forecast
8.4.2 Mexico
8.4.2.1 Market Trends
8.4.2.2 Market Forecast
8.4.3 Others
8.4.3.1 Market Trends
8.4.3.2 Market Forecast
8.5 Middle East and Africa
8.5.1 Market Trends
8.5.2 Market Breakup by Country
8.5.3 Market Forecast
9 Drivers, Restraints, and Opportunities
9.1 Overview
9.2 Drivers
9.3 Restraints
9.4 Opportunities
10 Value Chain Analysis
11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 Amgen Inc.
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio
13.3.1.3 Financials
13.3.1.4 SWOT Analysis
13.3.2 BeyondSpring Inc.
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.2.3 Financials
13.3.3 Kyowa Hakko Kirin Co. Ltd. (Kirin Holdings Company Limited)
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio
13.3.3.3 Financials
13.3.3.4 SWOT Analysis
13.3.4 Pfizer Inc.
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio
13.3.4.3 Financials
13.3.4.4 SWOT Analysis
13.3.5 Sandoz Inc. (Novartis AG)
13.3.5.1 Company Overview
13.3.5.2 Product Portfolio
13.3.5.3 SWOT Analysis
13.3.6 Spectrum Pharmaceuticals Inc.
13.3.6.1 Company Overview
13.3.6.2 Product Portfolio
13.3.6.3 Financials
13.3.6.4 SWOT Analysis
13.3.7 Teva Pharmaceutical Industries Ltd.
13.3.7.1 Company Overview
13.3.7.2 Product Portfolio
13.3.7.3 Financials
13.3.7.4 SWOT Analysis
13.3.8 Viatris Inc.
13.3.8.1 Company Overview
13.3.8.2 Product Portfolio
13.3.8.3 Financials
*** 好中球減少症治療の世界市場に関するよくある質問(FAQ) ***
・好中球減少症治療の世界市場規模は？
→IMARC社は2024年の好中球減少症治療の世界市場規模を161億米ドルと推定しています。
・好中球減少症治療の世界市場予測は？
→IMARC社は2033年の好中球減少症治療の世界市場規模を240億米ドルと予測しています。
・好中球減少症治療市場の成長率は？
→IMARC社は好中球減少症治療の世界市場が2025年～2033年に年平均4.7%成長すると展望しています。
・世界の好中球減少症治療市場における主要プレイヤーは？
→「Amgen Inc., BeyondSpring Inc., Kyowa Hakko Kirin Co. Ltd. (Kirin Holdings Company Limited), Pfizer Inc., Sandoz Inc. (Novartis AG), Spectrum Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc.など ...」を好中球減少症治療市場のグローバル主要プレイヤーとして判断しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、最終レポートの情報と少し異なる場合があります。
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
